Pharmacology: Mechanism of Action: Solifenacin is a competitive, specific cholinergic-receptor antagonist.
Muscarinic receptors (M3) play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion. Solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of incontinence episodes.
Other special populations: Elderly: No dosage adjustment based on patient age is required.
Paediatric: The pharmacokinetics of solifenacin has not been established in Paediatric children and adolescents.
Gender: The pharmacokinetics of solifenacin are not influenced by gender.
Race: The pharmacokinetics of solifenacin are not influenced by race.
Renal impairment: The AUC and Cmax of solifenacin in mild and moderate renally impaired patients, was not significantly different from that found in healthy volunteers.
Pharmacokinetics in patients undergoing haemodialysis have not been studied.
Hepatic impairment: In patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) the Cmax is not affected, AUC increased with 60% and t½ doubled. Pharmacokinetics of solifenacin in patients with severe hepatic impairment have not been studied.